Experts
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Radiopharm Theranostics.
RELATED STOCKHEAD STORIES
Experts
MoneyTalks: Two reasons why today’s Aussie biotech sector is like the ’90s scramble for beachside property
Health & Biotech
ASX Biotech Stocks: Neurotech reports positive paediatric autism results and Arovella to close Perth R&D facility
Investor Guides
Investor Guide: Health & Biotech FY2023
Health & Biotech
ASX Health Stocks: Radiopharm wins US FDA Orphan status, set to accelerate treatment for rare bone cancer in kids
Health & Biotech
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs
Experts
MoneyTalks: Tony Locantro’s 3 contrarian biotech picks in a time of market volatility
Health & Biotech
ASX Health Stocks: Neuren, Imugene and RadioPharm have sights on new clinical trials
Stockhead TV
V-Con: Tim Boreham’s Hot Stock Picks for 2022
News
Market Highlights and 5 ASX Small Caps to watch on Tuesday
Health & Biotech
ASX Health Stocks: Clinical trials gather pace for Visioneering Tech, Anteris and other biotechs
Experts
Twenty-One of the Best: Tim Boreham’s Hot Stocks for 2022
Health & Biotech
ScoPo’s Powerplays: IDT wins big on COVID vaccines, but Healthcare IPOs look exhausted
Health & Biotech
Dr Boreham’s Crucible: Is Paul Hopper’s star power enough to get Radiopharm Theranostics beaming?
News